Massachusetts Financial Services Co. MA decreased its stake in shares of Dexcom (NASDAQ:DXCM) by 28.3% during the first quarter, HoldingsChannel reports. The firm owned 403,536 shares of the medical device company’s stock after selling 159,077 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Dexcom were worth $29,926,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. American International Group Inc. acquired a new position in Dexcom during the 4th quarter valued at approximately $116,000. SG Americas Securities LLC acquired a new position in Dexcom during the 1st quarter valued at approximately $175,000. Thompson Davis & CO. Inc. acquired a new position in Dexcom during the 4th quarter valued at approximately $137,000. CIBC Asset Management Inc acquired a new position in Dexcom during the 1st quarter valued at approximately $220,000. Finally, Atria Investments LLC acquired a new position in Dexcom during the 1st quarter valued at approximately $249,000.
Get Dexcom alerts:
DXCM has been the topic of a number of research reports. BTIG Research reiterated a “hold” rating on shares of Dexcom in a research note on Thursday, May 3rd. BidaskClub lowered shares of Dexcom from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. Zacks Investment Research upgraded shares of Dexcom from a “sell” rating to a “hold” rating in a research note on Friday, March 16th. Oppenheimer increased their price objective on shares of Dexcom from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, May 3rd. Finally, Northcoast Research reiterated a “buy” rating on shares of Dexcom in a research note on Sunday, March 4th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $69.79.
DXCM stock opened at $86.54 on Thursday. The company has a current ratio of 5.83, a quick ratio of 5.42 and a debt-to-equity ratio of 0.79. Dexcom has a one year low of $86.75 and a one year high of $87.40.
Dexcom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). The company had revenue of $184.40 million for the quarter, compared to analyst estimates of $172.66 million. Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The firm’s revenue was up 29.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.49) earnings per share. equities research analysts expect that Dexcom will post -0.52 earnings per share for the current year.
In related news, insider Terrance H. Gregg sold 10,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $65.51, for a total transaction of $655,100.00. Following the sale, the insider now owns 521,674 shares in the company, valued at $34,174,863.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Richard Doubleday sold 1,638 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $56.32, for a total transaction of $92,252.16. Following the sale, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,663,559.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 107,432 shares of company stock worth $8,779,262. 1.80% of the stock is owned by company insiders.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dexcom (NASDAQ:DXCM).